Rep. C. Scott Franklin Purchases Shares of Novo Nordisk A/S (NYSE:NVO)

Representative C. Scott Franklin (R-Florida) recently bought shares of Novo Nordisk A/S (NYSE:NVO). In a filing disclosed on April 11th, the Representative disclosed that they had bought between $1,001 and $15,000 in Novo Nordisk A/S stock on March 27th. The trade occurred in the Representative’s “FIDELITY ROTH IRA” account.

Representative C. Scott Franklin also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Novo Nordisk A/S (NYSE:NVO) on 3/27/2025.
• Purchased $50,001 – $100,000 in shares of Amazon.com (NASDAQ:AMZN) on 2/26/2025.
• Purchased $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 2/26/2025.
• Purchased $15,001 – $50,000 in shares of Lockheed Martin (NYSE:LMT) on 2/18/2025.
• Purchased $1,001 – $15,000 in shares of Lockheed Martin (NYSE:LMT) on 2/18/2025.
• Sold $1,000,001 – $5,000,000 in shares of The Baldwin Insurance Group (NASDAQ:BWIN) on 2/7/2025.
• Sold $15,001 – $50,000 in shares of The Baldwin Insurance Group (NASDAQ:BWIN) on 2/6/2025.
• Sold $50,001 – $100,000 in shares of Costco Wholesale (NASDAQ:COST) on 1/28/2025.
• Sold $1,001 – $15,000 in shares of Costco Wholesale (NASDAQ:COST) on 1/28/2025.

Novo Nordisk A/S Trading Down 2.4 %

NYSE:NVO opened at $64.46 on Wednesday. The stock has a fifty day simple moving average of $77.02 and a 200 day simple moving average of $92.75. The firm has a market capitalization of $289.27 billion, a price-to-earnings ratio of 19.59, a price-to-earnings-growth ratio of 0.90 and a beta of 0.61. Novo Nordisk A/S has a 1-year low of $59.32 and a 1-year high of $148.15. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Sell-side analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently announced a semi-annual dividend, which was paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st were given a dividend of $0.7874 per share. The ex-dividend date of this dividend was Monday, March 31st. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s payout ratio is 49.54%.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on NVO shares. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Stifel Nicolaus downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Kepler Capital Markets raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday, March 13th. Finally, StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Tuesday. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S has a consensus rating of “Moderate Buy” and a consensus target price of $145.25.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Bank of America Corp DE increased its holdings in Novo Nordisk A/S by 8.1% in the fourth quarter. Bank of America Corp DE now owns 15,492,384 shares of the company’s stock worth $1,332,655,000 after buying an additional 1,165,955 shares during the last quarter. GQG Partners LLC grew its position in Novo Nordisk A/S by 74.7% in the fourth quarter. GQG Partners LLC now owns 12,994,533 shares of the company’s stock worth $1,117,790,000 after acquiring an additional 5,556,460 shares in the last quarter. Loomis Sayles & Co. L P increased its stake in shares of Novo Nordisk A/S by 34.2% during the 4th quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company’s stock worth $995,397,000 after purchasing an additional 2,947,771 shares during the last quarter. Folketrygdfondet raised its holdings in shares of Novo Nordisk A/S by 0.5% during the 4th quarter. Folketrygdfondet now owns 8,903,938 shares of the company’s stock valued at $765,917,000 after purchasing an additional 40,313 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in shares of Novo Nordisk A/S by 1.5% in the 4th quarter. Renaissance Technologies LLC now owns 8,312,996 shares of the company’s stock valued at $715,084,000 after purchasing an additional 123,681 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

About Representative Franklin

Scott Franklin (Republican Party) is a member of the U.S. House, representing Florida’s 18th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Franklin (Republican Party) is running for re-election to the U.S. House to represent Florida’s 18th Congressional District. He declared candidacy for the 2026 election.

Scott Franklin was born in Thomaston, Georgia. Franklin graduated from Lakeland High School. He served in the U.S. Navy from 1986 to 2000 and the U.S. Navy Reserve from 2000 to 2012.

Franklin earned a B.S. from the United States Naval Academy in 1986 and an M.B.A. from Embry-Riddle Aeronautical University in 1994. Franklin’s career experience includes owning an insurance agency and working as a naval aviator with the U.S. Navy.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.